CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction Association of Cardiovascular Disease With Respiratory Disease Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association

Editorial2021 Jan 20;S0828-282X(21)00051-9.

JOURNAL:Can J Cardiol. Article Link

Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"

JG Howlett. Keywords: angiotensin receptor/neprilysin inhibitor; HF

Full Text PDF